Sam Brusco, Associate Editor03.14.23
HeartBeam, the cardiac technology company that developed a 3D-vector electrocardiogram (VECG) platform for heart attack detection, has acquired substantially all assets from LIVMOR, a digital health solutions firms with a patient-engaging remote monitoring system of critical physiological markers.
The deal extends HeartBeam’s reach in remote monitoring and detection. LIVMOR’s Halo+ atrial fibrillation (AFib) detection system was the world’s first prescription wearable for continuous cardiac rhythm monitoring, according to the company. Halo continuously monitors pulse rhythms to detect AF on-demand during the day and automatically at night.
This past February, HeartBeam partnered with LIVMOR to create a HeartBeam-branded version of LIVMOR’s Halo cloud-based software platform to connect doctors and patients. Using the Halo platform helped HeartBeam meet its FDA submission schedule for the HeartBeam AIMI software for acute care settings. The software offers 3D VECG comparison of baseline and symptomatic 12-lead ECG to better identify a heart attack.
HeartBeam bought LIVMOR’s intellectual property for an undisclosed amount. The IP includes three issued U.S. patents, LIVMOR tech, including the Halo AFib detection system, LIVMOR’s business contracts and relationships as well as all Samsung watch and tablet inventory.
HeartBeam also hired LIVMOR’s key technical employees.
“We’re very pleased to complete this acquisition as it is a natural fit and extension of our successful partnership with LIVMOR and our complementary goals to dramatically improve patient outcomes and to significantly reduce healthcare system costs,” Branislav Vajdic, Ph.D., HeartBeam CEO and founder told the press. “The fact that these intellectual property and product assets were developed by the technical team that is now part of HeartBeam means that we will be able to integrate the Halo cloud-based software platform with our AIMGO solution in an efficient and cost-effective manner.”
The deal extends HeartBeam’s reach in remote monitoring and detection. LIVMOR’s Halo+ atrial fibrillation (AFib) detection system was the world’s first prescription wearable for continuous cardiac rhythm monitoring, according to the company. Halo continuously monitors pulse rhythms to detect AF on-demand during the day and automatically at night.
This past February, HeartBeam partnered with LIVMOR to create a HeartBeam-branded version of LIVMOR’s Halo cloud-based software platform to connect doctors and patients. Using the Halo platform helped HeartBeam meet its FDA submission schedule for the HeartBeam AIMI software for acute care settings. The software offers 3D VECG comparison of baseline and symptomatic 12-lead ECG to better identify a heart attack.
HeartBeam bought LIVMOR’s intellectual property for an undisclosed amount. The IP includes three issued U.S. patents, LIVMOR tech, including the Halo AFib detection system, LIVMOR’s business contracts and relationships as well as all Samsung watch and tablet inventory.
HeartBeam also hired LIVMOR’s key technical employees.
“We’re very pleased to complete this acquisition as it is a natural fit and extension of our successful partnership with LIVMOR and our complementary goals to dramatically improve patient outcomes and to significantly reduce healthcare system costs,” Branislav Vajdic, Ph.D., HeartBeam CEO and founder told the press. “The fact that these intellectual property and product assets were developed by the technical team that is now part of HeartBeam means that we will be able to integrate the Halo cloud-based software platform with our AIMGO solution in an efficient and cost-effective manner.”